The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
Jason J. Luke, Manish R. Patel, George R. Blumenschein et al. · Nature Medicine · 2023
Abstract Tebotelimab, a bispecific PD-1×LAG-3 DART molecule that blocks both PD-1 and LAG-3, was investigated for clinical safety and activity in a phase 1 dose-escalation and cohort-expansion clinical trial in patients with solid tumors or hematologic malignancies and disease progression on previous treatment. Primary endpoints were safety and maximum tolerated dose of tebotelimab when administered as a single agent (n = 269) or in combination with the anti-HER2 antibody margetuximab (n = 84). Secondary endpoints included anti-tumor activity. In patients with advanced cancer treated with tebotelimab monotherapy, 68% (184/269) experienced treatment-related adverse events (TRAEs; 22% were grade ≥3). No maximum tolerated dose was defined; the recommended phase 2 dose (RP2D) was 600 mg once every 2 weeks. There were tumor decreases in 34% (59/172) of response-evaluable patients in the dose-escalation cohorts, with objective responses in multiple solid tumor types, including PD-1-refractory disease, and in LAG-3+ non-Hodgkin lymphomas, including CAR-T refractory disease. To enhance potential anti-tumor responses, we tested margetuximab plus tebotelimab. In patients with HER2+ tumors treated with tebotelimab plus margetuximab, 74% (62/84) had TRAEs (17% were grade ≥3). The RP2D was 600 mg once every 3 weeks. The confirmed objective response rate in these patients was 19% (14/72), including responses in patients typically not responsive to anti-HER2/anti-PD-1 combination therapy. ClinicalTrials.gov identifier: NCT03219268 .
Cited by 138 works. doi:10.1038/s41591-023-02593-0 Open-access PDF
Authors
- Jason J. Luke
- Manish R. Patel
- George R. Blumenschein
- Erika Paige Hamilton
- Bartosz Chmielowski
- Susanna Varkey Ulahannan
- Roisín M. Connolly
- Cesar Augusto Santa-Maria
- Jie Wang
- Shakeela Wazeen Bahadur
- Andrew James Weickhardt
- Adam Steven Asch
- Girish Mallesara
- Philip R. Clingan
- Monika Długosz‐Danecka
- Monika Tomaszewska‐Kiecana
- Halyna Pylypenko
- Nada Hamad
- Hedy Lee Kindler
- Bradley James Sumrow
References
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Revised Response Criteria for Malignant Lymphoma
- Nivolumab plus Ipilimumab in Advanced Melanoma
- PD-1 and Its Ligands in Tolerance and Immunity
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- A Confidence Interval for the Median Survival Time
- T cell exhaustion
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma